This Week in Infectious Disease — Aug 21, 2026

Welcome to This Week in Infectious Disease. This week we're covering 10 notable papers spanning antimicrobial therapy and stewardship in resource-limited and hospital settings, prevention through vaccines, vector control and supplementation, and infection in immunocompromised and chronically infected hosts. Let's dive in.

We'll start with two papers that speak directly to how we choose and de-escalate antibiotics. In The Lancet Infectious Diseases, the ACT-South Asia trial tested whether adding cefixime to azithromycin improves outcomes in uncomplicated typhoid fever [1]. Basnyat and colleagues randomised more than eighteen hundred adults and children across Nepal, Bangladesh and Pakistan with suspected or blood culture-confirmed typhoid to seven days of azithromycin plus cefixime, or azithromycin plus placebo, in a properly blinded design. The composite treatment failure rate was identical in the two arms, at about five percent in each. In the smaller subgroup with culture-confirmed disease, failure was numerically lower with combination therapy, around eleven percent versus sixteen percent, but that difference was not statistically significant and the trial provides no evidence supporting the combination. Adverse events were the same in both groups. The practical message is clean: azithromycin alone remains the treatment of choice, and adding a second oral agent buys you extra cost and extra selection pressure without demonstrable benefit. Alongside that, Clinical Infectious Diseases published a randomised trial from Kim and colleagues comparing standard blood culture workflow against standard workflow plus a rapid multiplex molecular panel run on positive blood cultures, with antimicrobial stewardship support in both arms [2]. Among 418 patients, the median time to the first effective antibiotic modification fell from roughly sixty-five hours to about twenty-three hours, and that advantage held for Gram-negatives, Gram-positives and yeasts, in and out of the intensive care unit, and during off-hours. Persistent bloodstream infection was about half as common with rapid testing. Importantly, there was no difference in thirty-day mortality or length of stay, so this is a stewardship and pathogen-clearance argument, not yet a survival argument.

That matters because of the third paper in this group, the ACORN-HAI cohort in The Lancet Infectious Diseases, which is the largest prospective picture we have of resistant health-care-associated infection in Asia [3]. Mo and colleagues followed nearly ten thousand patients across 41 hospitals in 19 countries with hospital-acquired or health-care-associated bloodstream infection or ventilator-associated pneumonia. Just under three quarters of infection episodes involved resistant organisms, and Gram-negatives dominated. Crude twenty-eight-day mortality among resistant infections was close to thirty-eight percent, rising above half for carbapenem-resistant Acinetobacter. Attributable mortality was highest in ventilator-associated pneumonia, in children and younger adults, and in lower-middle-income countries. Perhaps the most sobering detail is therapeutic: most carbapenem-resistant Gram-negative infections were still being treated with carbapenems or polymyxins, which tells you that access to newer beta-lactam–beta-lactamase inhibitor combinations, not just diagnostics, is the binding constraint in much of the region.

Turning to prevention, three papers approach the problem from different angles. In JAMA, the ZIPS-2 trial randomised one hundred Ugandan children aged one to under five with sickle cell anaemia to twenty milligrams of daily zinc sulfate or placebo for six months, on a background where all participants were on hydroxyurea [4]. Namazzi and colleagues recorded eighty all-cause infections in the zinc arm versus one hundred and twenty-four on placebo, which works out to roughly a forty percent reduction in the infection rate after adjustment, with no adverse events forcing discontinuation and no loss to follow-up. This is a single-site trial of one hundred children, so it needs replication, but it is a cheap, safe intervention layered on top of hydroxyurea in a population where infection still drives mortality. On the vaccine side, The Lancet Infectious Diseases reported a phase 2a trial of SF2a-TT15, a synthetic carbohydrate conjugate vaccine against Shigella flexneri 2a, in Kenyan adults, children and 216 infants who received it alongside routine measles-rubella vaccination [6]. Sawe and colleagues used an age-descending, dose-escalating design testing two and ten microgram doses with and without aluminium adjuvant, with safety and infant immunogenicity as the co-primary outcomes. Given that Shigella is a leading cause of childhood diarrhoeal death and an increasingly resistant one, advancing a conjugate candidate into the target infant population in an endemic setting is the key step here. And on vector control, a cluster-randomised trial in the same journal tested a dual-action insecticidal coating containing microencapsulated pyriproxyfen and alpha-cypermethrin applied to indoor ground-level water containers in Cúcuta, Colombia [10]. Cardenas and colleagues randomised twenty clusters of roughly two thousand households each, and reached almost ninety percent of eligible households. Over twelve months, dengue incidence in intervention clusters was cut by roughly forty-five percent relative to controls, with substantial falls in house infestation and pupae-per-person indices, at an estimated direct cost of two United States dollars per household per year. A single application, at that price point, makes this a credible complementary tool for endemic urban settings.

The final theme is infection in compromised and chronically infected hosts. Clinical Infectious Diseases published the E-IPA study, a French multicentre retrospective cohort of 262 solid organ and stem cell transplant recipients with infective endocarditis, propensity-matched against more than fifteen hundred non-transplant controls [7]. Cachera and colleagues found a distinctly different microbiology: Staphylococcus aureus led at a quarter of cases, followed by enterococci and coagulase-negative staphylococci, with fewer streptococcal cases and more enterococcal, coagulase-negative staphylococcal, Gram-negative and fungal endocarditis than in matched controls. Timing mattered — fungal and coagulase-negative staphylococcal disease clustered in the first post-transplant year, streptococcal disease later. Transplant status independently raised one-year mortality by roughly seventy percent, though ninety-day mortality was no different, suggesting the excess risk accrues over the longer term. The actionable point is that empirical coverage in a transplant recipient with suspected endocarditis should be shaped by how long ago they were transplanted. Also in Clinical Infectious Diseases, Fisher and colleagues reported a ten-centre prospective cohort of 819 paediatric allogeneic stem cell transplant recipients followed for 180 days in the era of routine adenovirus PCR surveillance [8]. Among surveilled children, adenovirus infection occurred in about twenty-seven percent and DNAemia in about sixteen percent, with proven or probable adenovirus disease in roughly one in nine of the whole cohort. The attributable case-fatality rate among those with disease was about fourteen percent. Notably, children who were both adenovirus IgG positive and stool PCR positive before transplant had an infection incidence above fifty percent, which offers a practical way to identify a high-risk group for enrolment in future antiviral trials.

Rounding out this theme, two HIV papers ask how much care and how many drugs are actually necessary. In Clinical Infectious Diseases, Chivite and colleagues randomised 321 virologically suppressed people with HIV categorised as low complexity to annual versus standard six-monthly visits over two years [5]. Virological control was essentially identical, around eighty-six percent by intention-to-treat in both arms and above ninety-seven percent per-protocol, but I want to be precise here: formal non-inferiority was not statistically demonstrated against the prespecified margin. What the trial did show was a significant rise in patient satisfaction and a roughly twenty-five percent reduction in HIV-related direct costs with annual visits. Treat it as encouraging but not definitive. And in Open Forum Infectious Diseases, the CARAVEL cohort followed 304 people in routine French care starting dolutegravir–lamivudine, both treatment-naive and switching while suppressed [9]. Around ninety percent of treatment-naive participants achieved suppression by six months with no virological failure, and ninety-four percent of switchers stayed suppressed. Only nine pretreated participants had virological failure, with a single documented M184V emerging in the setting of non-adherence, and weight change was not significant in either group.

If you only have time for one paper this week, make it the ACT-South Asia typhoid trial in The Lancet Infectious Diseases [1]. It is a large, rigorously blinded trial that answers a question clinicians in endemic settings face daily, and it settles it in favour of the simpler, narrower regimen.

Here are the key takeaways from this week in Infectious Disease. First, for uncomplicated typhoid fever, azithromycin monotherapy stands — adding cefixime did not reduce treatment failure. Second, rapid molecular panels on positive blood cultures cut time to effective therapy by roughly two thirds and reduced persistent bacteraemia, but did not change mortality or length of stay. Third, resistant health-care-associated infection in Asia carries a twenty-eight-day mortality near forty percent, and most carbapenem-resistant Gram-negative infections are still being treated with carbapenems or polymyxins — access to effective drugs is as urgent as stewardship. Fourth, cheap prevention delivered: daily zinc cut all-cause infection by about forty percent in young Ugandan children with sickle cell anaemia, and a two-dollar insecticidal container coating cut dengue incidence by nearly half in Colombia. And fifth, in transplant recipients, both endocarditis microbiology and adenovirus risk are shaped by time since transplant and pre-transplant status — let those factors drive your empirical and surveillance decisions.

That's your roundup for This Week in Infectious Disease. The full transcript and references are available on the episode page in your AudioScholar library. This is an AI-curated summary — for clinical decisions, always consult primary sources and current guidelines. See you next week.

If this weekly briefing is useful, follow the show in your podcast app so new episodes arrive automatically. And a quick rating on Apple Podcasts or Spotify helps other physicians discover the show.

This is an automated summary generated by artificial intelligence, which can make mistakes. Always review the original source materials.